Everest Medicines just recently revealed that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has actually accepted the application for localized production for VELSIPITY(R) (etrasimod arginine tablets) and given Priority Review. Localized production of VELSIPITY(R) is anticipated to start in 2027, even more boosting supply capability and supply security in China and throughout the Asia-Pacific area. The approval marks development in the Company’s prepared commercialization of VELSIPITY(R).
The VELSIPITY(R) localized production task has actually been advancing progressively considering that its launch at the Company’s international production center in Jiashan in March 2025, with continuous efforts concentrated on innovation transfer, procedure optimization and preparations for localized production. Upon start of production, the center is anticipated to have a yearly production capability of approximately 50 million tablets, assisting to enhance supply stability, lower production expenses and enhance functional performance, while supporting the commercialization of VELSIPITY(R).
VELSIPITY(R) was authorized by NMPA in February, 2026, for the treatment of adult clients with reasonably to seriously active UC who have had an insufficient reaction, lost action, or were intolerant to either standard treatment or a biologic representative. As a next-generation extremely selective S1P receptor modulator, VELSIPITY(R) uses the capacity for fast beginning of action, and lasting scientific remission and mucosal recovery through an oral, once-daily program for adult clients with reasonably to seriously active UC. The very first prescription of VELSIPITY(R) in China was released in March 2026, making its entry into scientific usage. Along with its quick commercialization, the Company is actively taking part in settlements for the addition of VELSIPITY(R) in the National Reimbursement Drug List (NRDL).
VELSIPITY(R) has actually been authorized in numerous areas accredited to Everest Medicines, consisting of mainland China, Hong Kong SAR, Macao SAR, Singapore, and South Korea, and is anticipated to get NDA approval in Taiwan, China in the 2nd half of 2026.
On the scientific front, Ulcerative colitis (UC) is a persistent, relapsing, non-specific inflammatory bowel illness. In China, the occurrence and frequency of UC continue to increase, with a clear pattern towards more youthful clients. The client population is forecasted to increase from around 0.98 million in 2025 to 1.50 million by 20311,2.
Numerous research studies of VELSIPITY(R) provided at the 21st Congress of the European Crohn’s and Colitis Organization (ECCO 2026) and the 14th Annual Meeting of the Asian Organization for Crohn’s and Colitis (AOCC 2026) even more supported its scientific profile. The information showed continual effectiveness with constant treatment for as much as 3 years3. Long lasting advantage was observed in clients who had actually gotten just 5-ASA/thiopurine treatment, and in biologic-experienced patients4,5. Advantage was likewise shown in clients with slightly to reasonably active UC6, with beneficial long-lasting security and tolerability preserved for as much as 5 years of treatment7. These findings even more reinforce the medical proof base of VELSIPITY(R).
The scientific worth of VELSIPITY(R) has actually been acknowledged in prominent global medical standards. Following its addition in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY(R) was likewise consisted of in the 2025 American College of Gastroenterology (ACG) Clinical Guideline, the 2026 Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines and the 2026 European Crohn’s and Colitis Organization (ECCO) Guidelines.
Everest Medicines has a commercial-scale worldwide production website in Jiashan, Zhejiang Province. It has actually developed a total GMP production quality management system adhering to Chinese, EU and WHO requirements and holds the production license.
Localized production is anticipated to even more boost the business capacity of VELSIPITY(R) by enhancing supply dependability and functional performance in China. Supported by Everest Medicines’ A2MS business os and lean management abilities, the localized production of VELSIPITY(R) will enhance the structure for its ongoing growth in China and additional construct the Company’s business abilities in autoimmune illness, supporting its long-lasting development.
Referral
1. Shao B, et al. Front Public Health. 2022 Oct 25; 10:1032679.
2. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015; 12( 12 ):720 -727.
3. D T Rubin, et al. Journal of Crohn’s and Colitis, 2026, jjaf231.774.
4. B E Sands, et al. Journal of Crohn’s and Colitis, 2026, jjaf231.1105.
5. C Zheng, et al. Journal of Crohn’s and Colitis, 2026, jjaf231.1046.
6. D T Rubin, et al. Journal of Crohn’s and Colitis, 2026, jjaf231.100.
7. D T Rubin, et al. Journal of Crohn’s and Colitis, 2026, jjaf231.1256.
Subject: Press release summary